Skip to main content
No profile photo available

Mei Y. Koh, PhD

Languages spoken: English

Selected Publications

Journal Article

  1. Koh MY, Nguyen V, Lemos R Jr, Darnay BG, Kiriakova G, Abdelmelek M, Ho TH, Karam J, Monzon FA, Jonasch E, Powis (2015). Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activation of HIF2 in clear-cell renal cell carcinoma. Cancer research, 75(2), 316-29.
  2. Koh MY, Lemos R Jr, Liu X, Powis (2011). The hypoxia-associated factor switches cells from HIF-1¿- to HIF-2¿-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer research, 71(11), 4015-27.
  3. Grandjean G, de Jong PR, James B, Koh MY, Lemos R, Kingston J, Aleshin A, Bankston LA, Miller CP, Cho EJ, Edupuganti R, Devkota A, Stancu G, Liddington RC, Dalby K, Powis (2016). Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1¿ Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. Cancer research, 76(14), 4259-4269.
  4. Maruggi M, Layng FI, Lemos R Jr, Garcia G, James BP, Sevilla M, Soldevilla F, Baaten BJ, de Jong PR, Koh MY, Powis (2019). Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth. Cancer research, 79(22), 5839-5848.
  5. Koh MY, Gagea M, Sargis T, Lemos R Jr, Grandjean G, Charbono A, Bekiaris V, Sedy J, Kiriakova G, Liu X, Roberts LR, Ware C, Powis (2016). A new HIF-1¿/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice. Hepatology (Baltimore, Md.), 63(5), 1576-91.
  6. Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M, Tilby MJ, Pearson DG, Ottley CJ, Workman P, Frame MC, Dive (2004). Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. The Journal of biological chemistry, 279(44), 46113-21.
  7. Koh MY, Darnay BG, Powis (2008). Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation. Molecular and cellular biology, 28(23), 7081-95.
  8. Baker AF, Koh MY, Williams RR, James B, Wang H, Tate WR, Gallegos A, Von Hoff DD, Han H, Powis (2008). Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas, 36(2), 178-86.
  9. Koh MY, Spivak-Kroizman TR, Powis (2010). HIF-1alpha and cancer therapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 180, 15-34.
  10. Welsh SJ, Koh MY, Powis (2006). The hypoxic inducible stress response as a target for cancer drug discovery. Seminars in oncology, 33(4), 486-97.
  11. Koh MY, Powis (2012). Passing the baton: the HIF switch. Trends in biochemical sciences, 37(9), 364-72.
  12. Koh MY, Spivak-Kroizman TR, Powis (2009). Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clinical cancer research, 15(19), 5945-6.
  13. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Molecular cancer therapeutics, 7(1), 90-100.
  14. Koh MY, Powis (2009). HAF : the new player in oxygen-independent HIF-1alpha degradation. Cell cycle (Georgetown, Tex.), 8(9), 1359-66.
  15. Green YS, Sargis T, Reichert EC, Rudasi E, Fuja D, Jonasch E, Koh M (2019). Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Molecular cancer research, 17(5), 1220-1232.

News & Podcasts